Cargando…

Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease

The number of patients with nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) is increasing globally and is raising serious concerns regarding the increasing medical and economic burden incurred for their treatment. The progression of NASH to more severe conditions such as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kamata, Shotaro, Honda, Akihiro, Ishii, Isao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452531/ https://www.ncbi.nlm.nih.gov/pubmed/37627329 http://dx.doi.org/10.3390/biom13081264

Ejemplares similares

PPARα Ligand-Binding Domain Structures with Endogenous Fatty Acids and Fibrates
por: Kamata, Shotaro, et al.
Publicado: (2020)

Preparation of co-crystals of human PPARα-LBD and ligand for high-resolution X-ray crystallography
por: Kamata, Shotaro, et al.
Publicado: (2021)

Update on Pparγ and Nonalcoholic Fatty Liver Disease
por: Ables, Gene P.
Publicado: (2012)

Current status of imaging in nonalcoholic fatty liver disease
por: Li, Qian, et al.
Publicado: (2018)

Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate
por: Honda, Akihiro, et al.
Publicado: (2022)

Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
por: Drescher, Hannah K., et al.
Publicado: (2019)

Functional and Structural Insights into the Human PPARα/δ/γ Targeting Preferences of Anti-NASH Investigational Drugs, Lanifibranor, Seladelpar, and Elafibranor
por: Kamata, Shotaro, et al.
Publicado: (2023)

Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future
por: Yu, Jung Hwan, et al.
Publicado: (2023)

Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
por: Ahn, Sang Bong
Publicado: (2023)

Clostridioides difficile infection in patients with nonalcoholic fatty liver disease-current status
por: Kiseleva, Yana V, et al.
Publicado: (2023)

Role of Apolipoprotein A1 in PPAR Signaling Pathway for Nonalcoholic Fatty Liver Disease
por: Chen, Changxi, et al.
Publicado: (2022)

Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges
por: Ahmad, Muhammad Imran, et al.
Publicado: (2022)

Obesity and nonalcoholic fatty liver disease: current perspectives
por: Sarwar, Raiya, et al.
Publicado: (2018)

Lanzhang Granules Ameliorate Nonalcoholic Fatty Liver Disease by Regulating the PPARα Signaling Pathway
por: Huang, Ping, et al.
Publicado: (2022)

The Effects of PPAR Agonists on Atherosclerosis and Nonalcoholic Fatty Liver Disease in ApoE(−/−)FXR(−/−) Mice
por: Lee, Yenna, et al.
Publicado: (2021)

Treating Nonalcoholic Fatty Liver Disease From the Outside In?
por: Flynn, Charles R.
Publicado: (2019)

Misregulation of PPAR Functioning and Its Pathogenic Consequences Associated with Nonalcoholic Fatty Liver Disease in Human Obesity
por: Videla, Luis A., et al.
Publicado: (2012)

Intervening TNF-α via PPARγ with Gegenqinlian Decoction in Experimental Nonalcoholic Fatty Liver Disease
por: Wang, Yun-liang, et al.
Publicado: (2015)

Fimasartan Ameliorates Nonalcoholic Fatty Liver Disease through PPARδ Regulation in Hyperlipidemic and Hypertensive Conditions
por: Lee, Yong-Jik, et al.
Publicado: (2017)

Sijunzi, Lizhong, and Fuzilizhong Decoction Alleviate Nonalcoholic Fatty Liver Disease through Activation of PPAR Pathway
por: Yang, Jiayao, et al.
Publicado: (2020)

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis †
por: Yamashita, Shizuya, et al.
Publicado: (2023)

Current Concepts and Management Approaches in Nonalcoholic Fatty Liver Disease
por: Attar, Bashar M., et al.
Publicado: (2013)

Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies
por: Vizuete, John, et al.
Publicado: (2017)

2D DIGE proteomic analysis highlights delayed postnatal repression of α-fetoprotein expression in homocystinuria model mice
por: Kamata, Shotaro, et al.
Publicado: (2015)

Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research
por: Berardo, Clarissa, et al.
Publicado: (2020)

Nonalcoholic Fatty Liver Disease
por: Filipović, Branka, et al.
Publicado: (2018)

Nonalcoholic fatty liver disease
por: Bebawi, Emmanuel, et al.
Publicado: (2023)

The gut microbiota of nonalcoholic fatty liver disease: current methods and their interpretation
por: van Best, Niels, et al.
Publicado: (2015)

Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice
por: Zhou, Jiang-Hua, et al.
Publicado: (2019)

The Current View of Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma
por: Kogiso, Tomomi, et al.
Publicado: (2021)

General Overview About the Current Management of Nonalcoholic Fatty Liver Disease
por: Ampuero, Javier
Publicado: (2022)

Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis Cirrhosis Confirmed by Liver Histology after 14 Years
por: Kawanaka, Miwa, et al.
Publicado: (2020)

Reduced Glutathione suppresses Oxidative Stress in Nonalcoholic Fatty Liver Disease
por: Irie, Makoto, et al.
Publicado: (2016)

Physical Activity Is Prospectively Associated With Adolescent Nonalcoholic Fatty Liver Disease
por: Anderson, Emma L., et al.
Publicado: (2016)

Involvement of Periodontal Disease in the Pathogenesis and Exacerbation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis: A Review
por: Kobayashi, Takashi, et al.
Publicado: (2023)

Effect of miR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease
por: Ding, Jiexia, et al.
Publicado: (2015)

Lentinan Protects against Nonalcoholic Fatty Liver Disease by Reducing Oxidative Stress and Apoptosis via the PPARα Pathway
por: Du, Tingyi, et al.
Publicado: (2022)

Regulation of PPAR-γ activity in lipid-laden hepatocytes affects macrophage polarization and inflammation in nonalcoholic fatty liver disease
por: Li, Xiao-Yun, et al.
Publicado: (2022)

Hyodeoxycholic acid ameliorates nonalcoholic fatty liver disease by inhibiting RAN-mediated PPARα nucleus-cytoplasm shuttling
por: Zhong, Jing, et al.
Publicado: (2023)

Risk factors and diagnostic biomarkers for nonalcoholic fatty liver disease-associated hepatocellular carcinoma: Current evidence and future perspectives
por: Ueno, Masayuki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tk5fosmr5jal932t5u5raecta5